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background:  Cangrelor is an intravenous ADP receptor antagonist that leads to potent and reversible inhibition of platelet aggregation. 
The relative efficacy and safety of some antiplatelet drugs in women have been disputed. We therefore evaluated the efficacy and safety of 
cangrelor in women undergoing PCI.
methods:  The CHAMPION-PHOENIX trial randomized 11,145 patients undergoing elective or urgent PCI to cangrelor or clopidogrel 
(300mg or 600mg loading dose). The primary efficacy endpoint was a composite of death, MI, ischemia-driven revascularization or stent 
thrombosis (ST) at 48 hours after randomization; the key secondary end point was ST at 48 hours. The primary safety end point was 
GUSTO severe bleeding at 48 hours.
Results:  Of subjects enrolled, 3051 (28%) were female. Cangrelor reduced the odds of the primary endpoint by 33% in women (OR 0.67, 
0.50-0.92; P=0.01) and reduced the odds of ST by 61% (0.39, 0.20-0.77, P=0.005) compared with clopidogrel. The odds of severe bleeding 
were similar for women treated with cangrelor versus clopidogrel (0.3% vs 0.2%, P=0.52); the odds of moderate or severe bleeding 
were higher for cangrelor-treated women (1.3% vs 0.5%, P=0.02). The net clinical benefit (primary efficacy and safety endpoint) favored 
cangrelor vs clopidogrel in women (OR 0.69, 0.51-0.93, P=0.02, Figure).
conclusion:  In CHAMPION-PHOENIX, cangrelor reduced the odds of major adverse cardiovascular events and ST in women and 
appeared to offer greater net clinical benefit than clopidogrel.
